X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Cancer Risk Leads Pfizer Recall Blood Pressure Drug From US

Content Team by Content Team
28th April 2022
in News
US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

Pfizer’s recall saga has now reached the United States, after elevated concentrations of potential carcinogens forced the company to pull multiple products in Canada. After testing revealed quantities of a nitrosamine—Nnitroso-quinapril—above daily recommended limits, Pfizer is recalling five lots of Accupril pills, commonly known as quinapril HCL.

Nitrosamines are found in a wide range of foods, including cured and barbecued meats, dairy products, and vegetables. Everybody is susceptible to nitrosamines in some way, and cancer is only a result of long-term exposure to high levels of nitrosamines. Accupril is a blood pressure medication that has been licenced for the treatment of hypertension. According to Pfizer, it’s also prescribed to treat heart issues as an add-on therapy to diuretics or digitalis.

Pfizer said it had not acquired any safety evidence relating to the recalled medicines as of the week ending 23rd April 22.  Accupril has a 30-year safety track history, according to the company, and it believes the benefits of the drug exceed the dangers based on current research.

Although long-term consumption of Nnitroso-quinapril has been linked to an elevated cancer risk in humans, there is no imminent threat to patients using this drug, Pfizer said in a statement on the FDA’s website. Patients who are presently taking the drugs should discuss alternative therapies with their physician or health care provider. Between December 2019 and April 2022, Pfizer delivered the five Accupril lots across the United States and Puerto Rico.

The 90-count bottles of 10-, 20-, and 40-mg Accupril were slated to expire between the end of March and May of next year. In recent years, nitrosamines have been implicated in a slew of recalls, most prominently of valsartan blood pressure medications and metformin diabetes medications. Pfizer’s Chantix recall in 2021 was likewise driven by an excess of nitrosamines. Meanwhile, Pfizer has also recalled two different batches of blood pressure medicine in Canada because of nitrosamine concerns.

Meanwhile, in Canada, Pfizer recently recalled two separate blood pressure medication batches due to nitrosamine concerns. These medications were Accuretic, for which Pfizer withdrew all lots in Canada, and Inderal, for which Pfizer recalled 15 batches.

Previous Post

FDA Seeks To Know How Prescription Drug Risks Are Weighed

Next Post

With Biologics Spread Catalent Buys NJ Cell Therapy Plant

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Catalent To Open New Clinical Supply Facility In San Diego

With Biologics Spread Catalent Buys NJ Cell Therapy Plant

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In